| Literature DB >> 27713287 |
Toshiaki Aoki1,2, Kensuke Ohnishi1,2, Masaaki Kimoto3, Satoshi Fujieda3, Kouji Kuramochi2,3, Toshifumi Takeuchi3, Atsuo Nakazaki1, Nobuo Watanabe3, Fumio Sugawara2,3, Takao Arai3, Susumu Kobayashi4,5.
Abstract
We developed an efficient, stereoselective synthetic method for the diketopiperazine moiety of neoechinulin A and its derivatives. The intramolecular cyclization at 80 ºC proceeded with minimal racemization of the stereogenic center at C-12 on neoechinulin A, even though the cyclization at 110 ºC caused partial racemization. In contrast with these results, the cyclization on diketopiperazine of 8,9-dihydroneoechinulin A derivatives did not cause epimerization of the stereogenic centers, even at 110 °C. We examined the structure-activity relationships for the cytoprotective activity against cytotoxicity induced by 3-morpholinosydnonimine (SIN-1) in nerve growth factor (NGF)-differentiated PC12 cells. The C-8/C-9 double bond, but not the stereogenic center derived from alanine, was found to play a key role in the cytoprotective activity.Entities:
Keywords: cytoprotective activity; intramolecular cyclization; neoechinulin A
Year: 2010 PMID: 27713287 PMCID: PMC4034020 DOI: 10.3390/ph3041063
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1The structure of natural neoechinulin A (1).
Preparation of optically pure (–)-neoechinulin A.
|
|
| ||
|---|---|---|---|
| 1 | 110 | 43 | 81 |
| 2 | 80 | 58 | 95 |
Isolated yield of (–)-1 from (+)-3. The enantiomeric excess was determined by chiral HPLC (DAICEL AD-H; hexane : 2-propanol = 9 : 1). Adapted from [7,8]
Scheme 1Preparation of optically pure (+)-neoechinulin A.
Preparation of preechinulin (4).
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | benzene | 80 | 7 | 73 |
| 2 | toluene | 110 | 1 | 83 |
Isolated yield of 4 from 5. Adapted from [5].
Scheme 2Preparation of compound 7(Adapted from [5]).
Cytoprotective activity of neoechinulin A stereoisomers against SIN-1-induced cell death in NGF-differentiated PC12 cells. a
|
|
|
|
|
|---|---|---|---|
| vehicle | 31.4 ± 2.0 | 0 | [ |
| (–) | 89.6 ± 11.2 | 113.9 | |
| (+) | 82.5 ± 11.6 | 100.0 | |
| vehicle | 9.7 ± 13.2 | 0 | [ |
| (–) | 49.7 ± 8.3 | 100 | |
| 7.0 ± 7.0 | –6.8 | ||
| 12.5 ± 10.2 | 7.1 |
PC12 cells were differentiated with NGF for 3 days, followed by treatment with vehicle (control) or each compound for an additional 24 hr, and then challenged with SIN-1 for 24 hr. Viability (% of non-SIN-1-treated cells) was assessed by either cell-counting kit-8 or LDH assay. The values were expressed as mean ± S.D. from at least three independent experiments. [4,5]. p < 0.01 versus respective vehicle-treated control.